Eli Lilly has seen tremendous growth from its new GLP-1 drugs, which people have been using for weight loss. Sales growth should continue as the company increases production and looks to win ...

Paulo Nunes dos Santos / Bloomberg via Getty Images Eli Lilly will report third-quarter earnings Wednesday morning, with the focus remaining on the production and sales of its popular weight-loss ...

Eli Lilly has seen massive returns this year and is one of the most expensive healthcare stocks in the world. Its new products have strong growth prospects, but their potential may still be ...

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are ...

Coming off a brutal 41-10 loss to Texas A&M, Missouri head coach Eli Drinkwitz was eager to see the way his team would respond. Here's all he had to say after the team's win to round out its non ...

Also Read: Eli Lilly’s Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron’s Dupixent In the LUCENT-3 trial, mirikizumab helped patients ...

The Food and Drug Administration on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, from its shortage list ...

Eli Lilly is expanding its innovation digs to Beijing, opening two research centers called the Eli Lilly China Medical Innovation Center and Lilly Gateway Labs. The newest Gateway Lab is the ...

The victory marks the Commodores' first-ever win over an opponent ranked in the top five of the AP poll, highlighted by a standout performance from tight end Eli Stowers — a key transfer and ...

Nico Chen has given his Buy rating due to a combination of factors including Eli Lilly’s strong revenue growth and the potential expansion of its diabetes medication Mounjaro. Chen recognizes ...

Over the last couple of years, pharmaceutical giant Eli Lilly (NYSE: LLY) has made a splash in the red-hot weight loss space. The company's path-breaking innovation in using glucagon-like peptide ...

A change in the dosing regimen of Eli Lilly’s Alzheimer’s drug Kisunla resulted in a lower rate of brain swelling among patients in a clinical trial, new data reported Tuesday show.